{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yogev O"],"funding":["RCUK | MRC | Medical Research Foundation","Bill and Melinda Gates Foundation","Wellcome Trust"],"pagination":["277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10019795"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["Expanding the arsenal of prophylactic approaches against SARS-CoV-2 is of utmost importance, specifically those strategies that are resistant to antigenic drift in Spike. Here, we conducted a screen of over 16,000 RNAi triggers against the SARS-CoV-2 genome, using a massively parallel assay to identify hyper-potent siRNAs. We selected Ten candidates for in vitro validation and found five siRNAs that exhibited hyper-potent activity (IC50 < 20 pM) and strong blockade of infectivity in live-virus experiments. We further enhanced this activity by combinatorial pairing of the siRNA candidates and identified cocktails that were active against multiple types of variants of concern (VOC). We then examined over 2,000 possible mutations in the siRNA target sites by using saturation mutagenesis and c"],"journal":["Communications biology"],"pubmed_title":["From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis."],"pmcid":["PMC10019795"],"funding_grant_id":["MR/W005611/1","207498/Z/17/Z"],"pubmed_authors":["Battistoni G","Weissbrod O","Berkyurek AC","Douek DC","Hosmillo M","Hannon GJ","Falciatori I","Naamati A","Goodfellow I","Grossman I","Gagne M","Rasnic R","Erlich Y","Ilan S","Izuagbe R","Honeycutt CC","McCormick L","Bressan D","Johnston T","Yogev O"],"additional_accession":[]},"is_claimable":false,"name":"From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis.","description":"Expanding the arsenal of prophylactic approaches against SARS-CoV-2 is of utmost importance, specifically those strategies that are resistant to antigenic drift in Spike. Here, we conducted a screen of over 16,000 RNAi triggers against the SARS-CoV-2 genome, using a massively parallel assay to identify hyper-potent siRNAs. We selected Ten candidates for in vitro validation and found five siRNAs that exhibited hyper-potent activity (IC50 < 20 pM) and strong blockade of infectivity in live-virus experiments. We further enhanced this activity by combinatorial pairing of the siRNA candidates and identified cocktails that were active against multiple types of variants of concern (VOC). We then examined over 2,000 possible mutations in the siRNA target sites by using saturation mutagenesis and c","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-04T21:30:57.845Z","creation":"2024-11-13T09:32:05.212Z"},"accession":"S-EPMC10019795","cross_references":{"pubmed":["36928598"],"doi":["10.1038/s42003-023-04589-5"]}}